Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage III colorectal cancer

Oncology Reports

Volumn 20, Issue 6, 2008, Pages 1521-1526

  Ito, Isao ^a   Mukai, Masaya ^b   Ninomiya, Hiromi ^a   Kishima, Kyoko ^b   Tsuchiya, Kazutoshi ^a   Tajima, Takayuki ^b   Nakamura, Masato ^c   Makuuchi, Hiroyasu ^c  

^a TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

^b TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil leucovorin; Adjuvant chemotherapy; Colorectal cancer; Occult neoplastic cells; Oral immunochemotherapy; PSK (Krestin); Tegafur uracil

Indexed keywords

FLUOROURACIL; FOLINIC ACID; KRESTIN; UFT; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; COLON RESECTION; COLORECTAL CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PATIENT COMPLIANCE; PIGMENTATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RECTUM RESECTION; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; JAPAN; MODELS, STATISTICAL; NEOPLASM METASTASIS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 59249090619     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000174     Document Type: Article

References (40)

1. Multi-Institutional Registry of Large Bowel Cancer in Japan, Vol. 23, cases treated in 1994. Japanese Society for Cancer of the Colon and Rectum, Tokyo, 2002.
2. Knacks and Pitfalls: Surgery of the Colon, Rectum and Anus (2nd edition). Sugihara K (ed.), Bunkoudou Co., Ltd., Tokyo, 2004.
3. Guideline for Large Bowel Cancer in Japan. Japanese Society for Cancer of the Colon and Rectum, Tokyo, 2005.
4. Mukai M, Ito I, Mukoyama S, Tajima T, Saito Y, Nakasaki H, Sato S and Makuuchi H: Improvement of 10-year survival by Japanese radical lymph node dissection in patients with Dukes' B and C colorectal cancer: A 17-year retrospective study. Oncol Rep 10: 927-934, 2003.
5. Mukai M, Sato S, Komatsu N, Nishida T, Shiba K, Ito I, Nakasaki H and Makuuchi H: Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with Dukes' C colorectal cancer. Oncol Rep 10: 1165-1169, 2003.
6. Mukai M, Sato S, Komatsu N, Nishida T, Shiba K, Ito I, Nakasaki H and Makuuchi H: Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with curatively resected Dukes' B colorectal cancer. Oncol Rep 10: 1177-1181, 2003.
7. Mukai M, Sato S, Nakasaki H, Saito Y, Nishiumi N, Iwasaki M, Tokuda Y, Ogoshi K, Inoue H and Makuuchi H: Occult neoplastic cells in the lymph node sinuses and recurrence of primary breast, lung, esophageal and gastric cancer. Oncol Rep 11: 81-84, 2004.
8. Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi M: Accuracy of criteria for predicting the recurrence and metastasis of stage I and II gastric cancer without lymph node metastasis. Oncol Rep 12: 59-62, 2004.
9. Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Accuracy of criteria for predicting recurrence and metastasis in stage II and III gastric cancer with lymph node metastasis. Oncol Rep 12: 63-66, 2004.
10. Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Predicting the recurrence/metastasis of stage II and III breast cancer with lymph node metastasis. Oncol Rep 12: 303-306, 2004.
11. Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Predicting the recurrence/metastasis of stage I and II breast cancer without lymph node metastasis. Oncol Rep 12: 745-748, 2004.
12. Mukai M, Sato S, Nishida T, Komatsu N, Shiba K, Nakasaki H and Makuuchi H: Selection criteria for high risk and low risk groups of recurrence and metastasis in patients with primary colorectal cancer. Oncol Rep 10: 1753-1758, 2003.
13. TNM classification of malignant tumours (6th edition). John Wiley & Sons, Inc., New York, 2002.
14. Mukai M: Occult neoplastic cells and malignant microaggregates in lymph node sinuses: Review and hypothesis. Oncol Rep 14: 173-175, 2005.
15. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Tajima T, Nakasaki H and Makuuchi H: Prospective study on the recurrence/ metastasis of stage II/III colorectal and gastric cancer associated with occult neoplastic cells in lymph node sinuses: Three-year interim results. Oncol Rep 16: 405-410, 2006.
16. Mukai M, Oida Y, Tajima T, Kishima K, Ninomiya H, Sato S, Nakamura M, Nakasaki H and Makuuchi H: Alternating hepatic arterial infusion and systemic chemotherapy for stage IV colorectal cancer with synchronous liver metastasis. Oncol Rep 16: 865-870, 2006.
17. Wolmark N, Wieand S, Lembersky B, Colangelo L, Smith R and Pazdur R: A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: results of NSABP protocol C-06. J Clin Oncol 22: 3508, 2004.
18. Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G and Wolmark N: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24: 2059-2064, 2006.
19. Mukai M, Moriya H, Himeno S, Oida Y, Mukoyama S, Nishi T, Nakasaki H, Sato S and Makuuchi H: Efficacy of oral UFT plus leucovorin therapy for colon cancer with ovarian and multiple liver metastases: Report of two cases. Oncol Rep 8: 1079-1083, 2001.
20. Mukai M, Tajima T, Nakasaki H, Sato S, Ogoshi K and Makuuchi H: Efficacy of postoperative adjuvant oral immunochemotherapy in patients with Dukes' B colorectal cancer. Ann Cancer Res Ther 11: 201-214, 2003.
21. Mukai M, Tajima T, Nakasaki H, Sato S, Ogoshi K and Makuuchi H: Efficacy of postoperative adjuvant oral immunochemotherapy in patients with Dukes' C colorectal cancer. Ann Cancer Res Ther 11: 215-229, 2003.
22. Mukai M, Tokunaga N, Yasuda S, Mukoyama S, Itoh I, Kameya T, Ishikawa K, Iwase H, Suzuki T, Ishida H, Sadahiro S and Makukuchi H: Long-term survival after immunochemotherapy in a patient of juvenile colon cancer with peritoneal dissemination: A case report. Oncol Rep 7: 1343-1347, 2000.
23. Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, Nishiyama K, Amano T, Takahashi T, Murayama N, Oka H, Oya K, Noto T and Ogawa N: Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of the Colon and Rectum (Kanagawa). Dis Colon Rectum 35: 123-130, 1992.
24. Nakazato H, Koike A, Saji S, Ogawa N and Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 33: 1122-1126, 1994.
25. Sakamoto J, Hamada C, Kodaira S, Nakazato H and Ohashi Y: Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials. Jpn J Clin Oncol 29: 78-86, 1999.
26. Munemoto Y, Iida Y, Abe J, Saito H, Fujisawa K, Kasahara Y, Mitsui T, Asada Y and Miura S: Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: Association between host or tumor factors and survival. Int J Oncol 20: 403-411, 2002.
27. Koda K, Miyazaki M, Sarashina H, Suwa T, Saito N, Suzuki M, Ogawa K, Watanabe S, Kodaira S, and Nakazato H: A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. Int J Oncol 23: 165-172, 2003.
28. Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S, Ishikawa H, Kawate S, Nakajima T and Morishita Y: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer. Br J Cancer 90: 1003-1010, 2004.
29. Sakamoto J, Morita J, Oba K, Matsui T, Kobayashi M, Nakazato H and Ohashi Y: Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: A meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 55: 404-411, 2006.
30. Machover D, Schwarzenberg L, Goldschmidt E, Tourani JM, Michalski B, Hayat M, Dorval T, Misset JL, Jasmin C, Maral R and Mathe G: Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep 66: 1803-1807, 1982.
31. Ito I, Mukai M, Ninomiya H, Kishima K, Tsuchiya K, Tajima T, Oida Y, Nakamura M and Makuuchi H: Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage II colorectal cancer. Oncol Rep 20: 1189-1194, 2008.
32. Mukai M, Sato S, Ninomiya H, Wakui K, Tsuchiya K, Komatsu N, Tajima T, Nakasaki H and Makuuchi H: Recurrence and 5-FU sensitivity of stage II/ III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep 14: 1505-1510, 2005.
33. Mukai M, Sato S, Ninomiya H, Wakui K, Tsuchiya K, Komatsu N, Tajima T, Nakasaki H and Makuuchi H: Recurrence and 5-FU sensitivity of stage I/II node-negative breast, lung, or gastric cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep 15: 815-820, 2006.
34. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller L: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343: 905-914, 2000.
35. Tournigand C, Achille TAE, Lledo G, Flesh M, Quinaux DM-ME, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and De Gramont A: FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
36. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Seri MD, Lopez M and Maiello E: Phase III randomized trial of FOLFIRI versus FOLFOX 4 in the treatment of advanced colorectal cancer: a multicenter study of Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23: 4866-4875, 2005.
37. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Matsui N, Nakamura M, Nakasaki H and Makuuchi H: Sensitivity to CPT-11 and platinum derivatives for stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep 17: 1027-1032, 2007.
38. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Matsui N, Nakamura M, Nakasaki H and Makuuchi H: Sensitivity to CPT-11 and platinum derivatives for stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep 17: 1045-1050, 2007.
39. Feinstein AR, Sosin DM and Wells CK: The Will Rogers phenomenon: stage migration and new techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312: 1604-1608, 1985.
40. Bunt AMG, Hermans J, Smit VTHBM, van de Velde CJH, Fleuren GL and Bruijn JA: Surgical/pathologic stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 13: 19-25, 1995.